{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:00:06Z","timestamp":1792051206389,"version":"4.4.0"},"reference-count":51,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The SARS-CoV-2 pandemic commenced in 2019 and is still ongoing. Neither infection nor vaccination give long-lasting immunity and, here, in an attempt to understand why this might be, we have compared the neutralizing antibody responses to SARS-CoV-2 with those specific for human immunodeficiency virus type 1 (HIV-1) and respiratory syncytial virus (RSV). Currently, most of the antibodies specific for the SARS-CoV-2 S protein map to three broad antigenic sites, all at the distal end of the S trimer (receptor-binding site (RBD), sub-RBD and N-terminal domain), whereas the structurally similar HIV-1 and the RSV F envelope proteins have six antigenic sites. Thus, there may be several antigenic sites on the S trimer that have not yet been identified. The epitope mapping, quantitation and longevity of the SARS-CoV-2 S-protein-specific antibodies produced in response to infection and those elicited by vaccination are now being reported for specific groups of individuals, but much remains to be determined about these aspects of the host\u2013virus interaction. Finally, there is a concern that the SARS-CoV-2 field may be reprising the HIV-1 experience, which, for many years, used a virus for neutralization studies that did not reflect the neutralizability of wild-type HIV-1. For example, the widely used VSV-SARS-CoV-2-S protein pseudotype has 10-fold more S trimers per virion and a different configuration of the trimers compared with the SARS-CoV-2 wild-type virus. Clarity in these areas would help in advancing understanding and aid countermeasures of the SARS-CoV-2 pandemic.<\/jats:p>","DOI":"10.3390\/v15020504","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T04:32:58Z","timestamp":1676262778000},"page":"504","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Understanding the SARS-CoV-2 Virus Neutralizing Antibody Response: Lessons to Be Learned from HIV and Respiratory Syncytial Virus"],"prefix":"10.3390","volume":"15","author":[{"given":"Nigel J.","family":"Dimmock","sequence":"first","affiliation":[{"name":"School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Easton","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.1038\/s41598-022-17605-1","article-title":"Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity","volume":"12","author":"Kim","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/vim.2022.0059","article-title":"Dynamics of neutralizing antibodies and binding antibodies to domains of SARS-CoV-2 spike protein in COVID-19 survivors","volume":"35","author":"Phakaratsakul","year":"2022","journal-title":"Viral Imunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Willyard, C. (2023). How quickly does COVID immunity fade? What Scientists know. Nature.","DOI":"10.1038\/d41586-023-00124-y"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"949787","DOI":"10.3389\/fimmu.2022.949787","article-title":"Saliva antibody-fingerprint of reactivated latent viruses after mild\/asymptomatic COVID-19 is unique in patients with myalgicencephalomyelitis\/chronic fatigue syndrome","volume":"13","author":"Apostolou","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1099\/0022-1317-75-12-3493","article-title":"Neutralization escape mutants of type A influenza virus are readily selected by antiserum from mice immunized with whole virus: A possible mechanism for antigenic drift","volume":"75","author":"Lambkin","year":"1994","journal-title":"J. Gen. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0264-410X(95)00183-2","article-title":"Longitudinal study of an epitope-biased haemagglutination-inhibition antibody response in rabbits immunized with type A influenza virus","volume":"14","author":"Lambkin","year":"1996","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1099\/0022-1317-76-4-889","article-title":"All rabbits immunized with type A influenza virions have a serum antibody haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B","volume":"76","author":"Lambkin","year":"1995","journal-title":"J. Gen. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"13205","DOI":"10.1021\/jacs.1c05435","article-title":"Fusion peptide of SARS-CoV-2 spike rearranges into a wedge inserted into bilayered micelles","volume":"143","author":"Koppisetti","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","article-title":"Viral membrane fusion","volume":"479\u2013480","author":"Harrison","year":"2015","journal-title":"Virology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Barrett, C.T., and Dutch, R.E. (2020). Viral membrane fusion and the transmembrane domain. Viruses, 12.","DOI":"10.3390\/v12070693"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity ofthe SARS-CoV-2 spike protein","volume":"180","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Klein, J.S., and Bjorkman, P.J. (2010). Few and far between: How HIV may be evading antibody avidity. PloS Path., 27.","DOI":"10.1371\/journal.ppat.1000908"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19123","DOI":"10.1073\/pnas.0607614103","article-title":"Influenza virus pleiomorphy characterized by cryoelectron tomography","volume":"103","author":"Harris","year":"2006","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e109728","DOI":"10.15252\/embj.2021109728","article-title":"Helical ordering of envelope-associated proteins and glycoproteins in respiratory syncytial virus","volume":"41","author":"Conley","year":"2022","journal-title":"EMBO J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/jvi.54.2.598-607.1985","article-title":"Mass and molecular composition of vesicular stomatitis virus: A scanning transmission electron microscopy analysis","volume":"54","author":"Thomas","year":"1985","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/viro.1993.1261","article-title":"Mechanisms of rabies virus neutralization","volume":"194","author":"Flamand","year":"1993","journal-title":"Virology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"587269","DOI":"10.3389\/fcimb.2020.587269","article-title":"SARS-CoV-2: Structure, biology, and structure-based therapeutics development","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1083\/jcb.133.3.559","article-title":"Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers","volume":"133","author":"Danieli","year":"1996","journal-title":"J. Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","article-title":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein","volume":"26","author":"Zost","year":"2020","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.chom.2020.06.010","article-title":"Neutralization of SARS-CoV-2 by destruction of the prefusion spike","volume":"28","author":"Huo","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10208","DOI":"10.1128\/JVI.75.21.10208-10218.2001","article-title":"Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event","volume":"75","author":"Edwards","year":"2001","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1099\/0022-1317-77-12-2931","article-title":"Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1","volume":"77","author":"Armstrong","year":"1996","journal-title":"J. Gen. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1128\/JVI.78.13.6938-6945.2004","article-title":"Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies","volume":"78","author":"Zhang","year":"2004","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-020-16638-2","article-title":"Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralizing antibodies in COVID-19 patients","volume":"11","author":"Poh","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1096\/fasebj.5.10.1712328","article-title":"Neutralization of HIV-1: A paradox of humoral proportions","volume":"5","author":"Nara","year":"1991","journal-title":"FASEB J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/jvi.69.1.101-109.1995","article-title":"Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120","volume":"69","author":"Moore","year":"1995","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bianchini, F., Crivelli, V., Abernathy, M.E., Guerra, C., Palus, M., Muri, J., Marcotte, H., Piralla, A., Redotti, M., and De Gasparo, R. (2023). Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. Sci. Immunol.","DOI":"10.1126\/sciimmunol.ade0958"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"Bewley","year":"2021","journal-title":"Nat. Protoc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fimmu.2018.00323","article-title":"Induction and subversion of human protective immunity: Contrasting influenza and respiratory syncytial virus","volume":"9","author":"Ascough","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1073\/pnas.94.25.13961","article-title":"Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant","volume":"94","author":"Karron","year":"1997","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/jmv.20349","article-title":"Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation","volume":"76","author":"Sastre","year":"2005","journal-title":"J. Med. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/infdis\/jiac189","article-title":"A phase 1\/2 study of a respiratory syncytial virus prefusion F vaccine with and without adjuvant in healthy older adults","volume":"226","author":"Baber","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/infdis\/jiab612","article-title":"A randomized phase 1\/2 Study of a respiratory syncytial virus prefusion F vaccine","volume":"225","author":"Walsh","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/S2666-5247(22)00097-0","article-title":"Nirsevimab: A promising therapy for RSV","volume":"3","author":"Venkatesan","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coi.2019.03.005","article-title":"Immunological goals for respiratory syncytial virus vaccine development","volume":"59","author":"Graham","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eaaj1879","DOI":"10.1126\/sciimmunol.aaj1879","article-title":"Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors","volume":"1","author":"Gilman","year":"2016","journal-title":"Sci. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1080\/19420862.2019.1654304","article-title":"Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV\/hMPV cross-neutralizing epitopes","volume":"11","author":"Xiao","year":"2019","journal-title":"Mabs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e14035","DOI":"10.15252\/emmm.202114035","article-title":"The respiratory syncytial virus (RSV) prefusion F-protein functional antibody repertoire in adult healthy donors","volume":"13","author":"Andreano","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/microbiolres12030044","article-title":"COVID-19 infection, vaccines, and immunity\u2014The antibody response requires detailed analysis","volume":"12","author":"Dimmock","year":"2021","journal-title":"Microbiol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/d41586-022-00997-5","article-title":"What\u2019s next for Alphafold and the AI protein-folding revolution","volume":"604","author":"Callaway","year":"2022","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.immuni.2018.07.009","article-title":"Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer Immunization","volume":"49","author":"Bianchi","year":"2018","journal-title":"Immunity"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature23301","article-title":"Rapid elicitation of broadly neutralizing antibodies to HIV by immunization of cows","volume":"548","author":"Sok","year":"2017","journal-title":"Nature"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/504\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:31:34Z","timestamp":1760121094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,11]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["v15020504"],"URL":"https:\/\/doi.org\/10.3390\/v15020504","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,11]]}}}